HIV study yields unexpected preliminary efficacy results.
Traynor
Kate
K
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015224:Dideoxynucleosides; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D019562:Viral Load; D000099227:Abacavir
D044966:Anti-Retroviral Agents; D003841:Deoxycytidine; D015224:Dideoxynucleosides; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D019259:Lamivudine; D009943:Organophosphorus Compounds; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir